Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | Outperform → Mkt Perform | Raymond James | |
| 6/18/2024 | $12.00 | Outperform | Raymond James |
| 5/25/2023 | $18.00 → $15.00 | Buy | Jefferies |
| 12/8/2022 | $11.00 | Buy | H.C. Wainwright |
| 9/23/2022 | $12.00 | Buy | Chardan Capital Markets |
| 8/24/2021 | $36.00 | Outperform | Wedbush |
| 8/24/2021 | $30.00 | Buy | Jefferies |
| 8/24/2021 | $30.00 | Overweight | Piper Sandler |
Raymond James downgraded Omega Therapeutics from Outperform to Mkt Perform
Raymond James initiated coverage of Omega Therapeutics with a rating of Outperform and set a new price target of $12.00
Jefferies resumed coverage of Omega Therapeutics with a rating of Buy and set a new price target of $15.00 from $18.00 previously
EFFECT - Omega Therapeutics, Inc. (0001850838) (Filer)
POS AM - Omega Therapeutics, Inc. (0001850838) (Filer)
S-8 POS - Omega Therapeutics, Inc. (0001850838) (Filer)
3 - Omega Therapeutics, Inc. (0001850838) (Issuer)
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
3 - Omega Therapeutics, Inc. (0001850838) (Issuer)